Could a pill shield your brain during radiation?

NCT ID NCT05417282

Completed Symptom relief Sponsor: ImmunoChem Therapeutics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a drug called MW151 in 27 adults with brain tumors who were receiving whole-brain radiation. The drug aims to reduce brain inflammation and prevent memory and thinking problems that often follow radiation. The study focused on safety, but also looked for signs that the drug might help protect cognitive function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MW151 (a drug that reduces brain inflammation)
What this could lead to: If it works, this could point toward a way to protect memory and thinking skills in people who need brain radiation for cancer.
What could go wrong: This is a very early Phase 1 trial with only 27 people, so it is too small to prove effectiveness. The main goal was safety, not whether it actually prevents cognitive decline.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE DYSFUNCTION, COGNITIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cognitive disorder Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE DYSFUNCTION, COGNITIVE DISORDER

Contacts and locations

Locations

Northwestern Memorial HealthCare, Central DuPage Hospital, Warrenville Cancer Center

Winfield, Illinois, 60555, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.